

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Atty. Dkt.: 620-301

Date: April 13, 2004

Sir:

Attached for filing is the patent application of:

Inventor: DAVIS et al

Entitled: USE OF SECRETIN-RECEPTOR LIGANDS IN TREATMENT OF CYSTIC FIBROSIS (CF) AND
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

and including attachments as noted below:

- ☐ Newly executed Declaration, ☒ Copy of Declaration from prior application, ☒ Abstract
☐ Please **delete** the following inventors in the continuation/division/continuation-in-part application:

Deleted persons:

38 pages of specification and claims (including 10 numbered claims), and
9 sheets of accompanying drawing/s for Figures 1 - 9.

☐ Record the attached assignment to _____, and return to the undersigned.

☐ Attached is a Power of Attorney.

☒ Priority is hereby claimed under 35 U.S.C. § 119 based on the following foreign applications:

Application Number**Country****Day/Month/Year Filed**

0016441.8

Great Britain

04/July/2000

, respectively, the entire content of which is hereby incorporated by reference in this application..

- ☐ Certified copy(ies) of foreign application(s) is/are attached.
☒ Certified copy(ies) filed on August 3, 2001 in prior appln. no. 09/897,412 filed July 3, 2001
☐ This application claims the benefit of Provisional Application No. _____, filed _____, the entire content of which is hereby incorporated by reference in this application.
☒ This application is a ☐ continuation/☒ division/☐ continuation-in-part of Application No. 09/897,412, filed July 3, 2001, the entire content of which is hereby incorporated by reference in this application.
☒ The prior application is assigned to Pharmagene Laboratories Ltd., Hertfordshire, United Kingdom.
☒ It is hereby requested that the Examiner consider the art cited in the parent application by applicant and/or the Examiner for the reasons stated therein. A listing of that art is attached.
☐ Applicant claims "small entity" status. ☐ "Small entity" statement attached.
☒ Please enter the attached preliminary amendment **prior** to calculation of filing fee:

- ☒ Also attached: ☒ Information Disclosure Statement; ☐ Non-Publication Request; ☐ Nucleotide and/or Amino Acid Sequence Submission; ☐ Statement deleting Inventor(s) named in prior application; ☒ Other: Nine (9) sheets formal drawings (Figs. 1-9); Request & copy of Sequence Listing filed 11/23/2001

FILING FEE IS BASED ON CLAIMS AS FILED LESS ANY HEREWITH CANCELED

Basic Filing Fee				\$	770.00
Total effective claims	10	- 20 (at least 20) =	0	x \$	18.00
Independent claims	4	- 3 (at least 3) =	1	x \$	86.00
If any proper multiple dependent claims now added for first time, add \$290.00 (ignore improper)				\$	0.00
				SUBTOTAL	\$ 856.00
If "small entity," then enter half (1/2) of subtotal and subtract				-\$	(0.00)
				SECOND SUBTOTAL	\$ 856.00
Assignment Recording Fee (\$40.00)				\$	0.00
				TOTAL FEE ENCLOSED	\$ 856.00

Any future submission requiring an extension of time is hereby stated to include a petition for such time extension.

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our **Account No. 14-1140**. A duplicate copy of this sheet is attached.

Correspondence Address:

Customer Number: **23117**

Telephone: (703) 816-4000

Facsimile: (703) 816-4100

BJS:pp

NIXON & VANDERHYE P.C.

By Atty: B. J. Sadoff, Reg. No. 36,663

Signature: _____

16834 U.S. PTO
10/822677
041304